Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - fenoterolhydrobromid, ipratropiumbromid - inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder - 1,25+0,5 mg/beholder

Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - fenoterolhydrobromid, ipratropiumbromid - inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder - 1,25 + 0,5 mg/behol.

Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

boehringer ingelheim int. gmbh - fenoterolhydrobromid, ipratropiumbromid - inhalationsspray, opløsning - 50 + 20 mikrog./pust

Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - fenoterolhydrobromid, ipratropiumbromid - inhalationsspray, opløsning - 50+20 mikrog./pust

Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - ipratropiumbromid, salbutamolsulfat - inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder - 2,5+0,5 mg/behold.

Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - fenoterolhydrobromid, ipratropiumbromid - inhalationsspray, opløsning - 50 + 20 mikrog./pust

Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmaxis europe limited - mannitol - inhalationspulver, hård kapsel

Danemark - danois - Lægemiddelstyrelsen (Danish Medicines Agency)

arrow generics limited - salbutamolsulfat - inhalationsvæske til nebulisator, opløsning - 1 mg/ml

Union européenne - danois - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasonpropionat - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - airexar spiromax er indiceret til brug kun hos voksne i alderen 18 år og ældre. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronisk obstruktiv lungesygdom (kol)airexar spiromax er indiceret til symptomatisk behandling af patienter med kol med fev1.

Union européenne - danois - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).